Eicosanodioate
Eicosanodioate is a 20-carbon dicarboxylic fatty acid, characterized by the presence of a carboxyl group at both ends of its hydrocarbon chain. It is primarily generated through the omega-oxidation pathway, an alternative route for fatty acid metabolism that complements the more widely known beta-oxidation pathway. This process typically occurs in the endoplasmic reticulum and peroxisomes, involving enzymes that oxidize the methyl (omega) end of a fatty acid, ultimately converting it into a dicarboxylic acid.
Biological Basis
The biological significance of eicosanodioate stems from its role in fatty acid metabolism and its potential as a metabolic indicator. While beta-oxidation is the predominant pathway for energy production from fatty acids, omega-oxidation can become more pronounced under conditions of high fatty acid load or when beta-oxidation is impaired. This pathway serves to detoxify or facilitate the excretion of fatty acids by increasing their water solubility. Genetic variations, such as single nucleotide polymorphisms (SNPs), can significantly influence the efficiency of various metabolic reactions and pathways, including those involved in fatty acid desaturation and glycerophospholipid synthesis, as demonstrated by associations with genes like FADS1. [1] Such genetic influences can lead to altered concentrations of various lipid metabolites, impacting overall metabolic balance. [1]
Clinical Relevance
Alterations in the levels of dicarboxylic fatty acids like eicosanodioate can serve as biomarkers for disruptions in fatty acid metabolism. Imbalances in lipid profiles, often influenced by genetic factors, are clinically relevant for conditions such as dyslipidemia, which is characterized by abnormal levels of lipids in the blood. [2] Furthermore, these lipid disturbances are significant risk factors for more severe health outcomes, including coronary artery disease . [2], [3] Genome-wide association studies (GWAS) have identified numerous genetic loci influencing lipid concentrations, highlighting the complex interplay between genetics and metabolic health . [2], [3]
Social Importance
Understanding the metabolism of compounds like eicosanodioate and the genetic factors that influence it holds considerable social importance. By elucidating these complex metabolic pathways and their genetic underpinnings, researchers can contribute to the development of personalized approaches to health and disease management. This knowledge can inform risk prediction for metabolic disorders, guide dietary and lifestyle recommendations, and potentially lead to novel therapeutic strategies. The integration of genetics with metabolomics, as exemplified by studies associating genetic variants with metabolite profiles, offers powerful insights into human health and disease. [1]
Limitations in Study Design and Statistical Power
The studies, while leveraging large cohorts and meta-analyses, still faced constraints in fully elucidating the genetic architecture of lipid levels. A significant challenge was the genomic coverage, with some studies utilizing 100K SNP arrays, which may be insufficient to capture all true associations within a gene region and could miss important causal variants. [4] This partial coverage limits the comprehensiveness of the genetic landscape explored. Furthermore, while meta-analysis aimed to enhance statistical power, the ability to detect modest genetic effects remained a limitation, with some studies having high power only for SNPs explaining a substantial portion (4% or more) of phenotypic variation. [5] This implies that numerous smaller-effect genetic contributions, which collectively can be significant, might have been overlooked, hindering a complete understanding of the trait.
Replication of findings across diverse cohorts also presented challenges, sometimes due to differing genetic coverage or insufficient power in individual studies. [5] Although efforts were made to replicate promising signals, non-replication at the SNP level could occur if different variants within the same gene are in strong linkage disequilibrium with an unknown causal variant across studies. [6] The reliance on imputation based on HapMap reference panels, while a strength, also introduced potential for imputation error rates, which could affect the accuracy of associations, particularly for less common variants. [3] These factors collectively impact the robustness and completeness of the identified genetic associations, emphasizing the need for even larger sample sizes and denser genomic coverage in future research.
Generalizability and Phenotypic Heterogeneity
A critical limitation across many of the genetic association studies is their predominant focus on populations of European ancestry, with non-European individuals often explicitly excluded from analyses. [7] This narrow demographic scope significantly restricts the generalizability of the findings to other global populations, as the frequency and effects of genetic variants, as well as the genetic architecture of complex traits, can vary considerably across different ancestries. Some studies also involved specific cohort types, such as founder populations, which may exhibit unique genetic characteristics that are not universally applicable to outbred populations. [6]
Despite efforts to standardize phenotype definitions and adjustments, variations in measurement protocols and covariate handling across diverse cohorts could introduce heterogeneity. For instance, while most studies adjusted lipid levels for age and sex, the specific methods for handling related individuals or averaging repeated measurements (e.g., in monozygotic twins or across multiple examinations) varied, potentially influencing variance estimates and comparability. [7] Although individuals on lipid-lowering therapies were generally excluded, subtle differences in phenotype ascertainment or unmeasured environmental factors across cohorts could still contribute to variability, complicating the interpretation and meta-analysis of results. [2]
Unaddressed Confounding and Remaining Genetic Complexity
The current research primarily focused on identifying direct genetic associations with lipid levels, often without extensively exploring the complex interplay of environmental factors or gene-environment interactions. [5] Genetic variants are known to influence phenotypes in a context-specific manner, with their effects potentially modulated by various environmental influences, such as diet, lifestyle, or medication. The absence of comprehensive investigations into such interactions means that important biological pathways involving environmental modifiers remain largely unexplored, potentially leading to an incomplete understanding of the trait's etiology and how genetic predispositions manifest under different conditions. [5]
Furthermore, despite the identification of numerous genetic loci, a substantial portion of the heritability for complex traits often remains unexplained, highlighting the existence of many causal variants yet to be discovered, particularly those with smaller effects, rare frequencies, or complex epistatic interactions. [6] For many of the statistically associated variants, the precise causal mutation within a genomic region often remains unidentified, and functional validation is still required to fully elucidate the biological mechanisms through which these genetic variants exert their effects on lipid metabolism. [8] This ongoing knowledge gap underscores the need for continued research to bridge the divide between statistical association and biological causality, including more refined genomic analyses and targeted functional studies.
Variants
The SLCO1B1 gene (Solute Carrier Organic Anion Transporter Family Member 1B1) encodes the OATP1B1 protein, a critical transporter predominantly found on the membrane of liver cells. This protein is responsible for facilitating the uptake of a wide array of compounds from the bloodstream into hepatocytes, where they can undergo further metabolism or be prepared for excretion. Its substrates encompass both endogenous substances, such as bilirubin and bile acids, and numerous exogenous compounds, including many commonly prescribed medications like statins. [1] The proper functioning of OATP1B1 is essential for maintaining systemic metabolic balance and for the efficient clearance of various substances from the body. [3]
The single nucleotide polymorphisms *rs58310495* and *rs12367888* are specific variants located within the SLCO1B1 gene, and they are known to influence the activity of the OATP1B1 transporter. While the precise functional consequences can differ based on the specific allele, certain genetic variations at these loci are associated with a reduced efficiency of the transporter protein. This diminished activity can lead to a less effective uptake of OATP1B1 substrates into the liver from the circulation. [6] As a result, individuals carrying these particular alleles may exhibit altered plasma concentrations of substances that are typically transported by OATP1B1, potentially impacting their overall metabolic profile or their response to certain medications. [9]
Variations in SLCO1B1, including *rs58310495* and *rs12367888*, have broad implications for the metabolism of various lipids and fatty acids, which could extend to compounds like eicosanodioate. Even if eicosanodioate is not a direct, primary substrate, alterations in the liver's general uptake capacity can significantly impact overall lipid processing and the circulating levels of diverse fatty acid metabolites. The liver plays a central role in the biosynthesis, breakdown, and transport of fatty acids and their derivatives, including complex glycerophospholipids such as PC aa C36:4 and PC aa C36:3, which are influenced by fatty acid desaturation pathways. [1] Therefore, modified OATP1B1 function can indirectly contribute to shifts in the broader metabolic landscape, influencing levels of compounds involved in lipid metabolism and potentially affecting traits like HDL cholesterol, LDL cholesterol, and triglyceride levels. [3]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs58310495 rs12367888 |
SLCO1B1 | gout 1-arachidonoyl-GPE (20:4n6) measurement X-02269 measurement eicosanodioate measurement metabolite measurement |
Classification, Definition, and Terminology
No information regarding the classification, precise definition, or specific terminology for 'eicosanodioate' is available in the provided research studies.
Biological Background of Eicosanodioate
Eicosanodioate, a dicarboxylic acid with a 20-carbon chain, is closely related to the broader family of eicosanoic acids, which are fundamental to human physiology. While the specific molecule eicosanodioate is not directly elaborated in the provided studies, its biological context can be understood through the extensive research on 20-carbon fatty acid metabolism, particularly polyunsaturated fatty acids (PUFAs), and their critical roles in cellular function, signaling, and systemic health. This background synthesizes information regarding the synthesis, regulation, and impact of these related 20-carbon fatty acids, providing a comprehensive view of their biological significance.
Metabolism of Polyunsaturated Fatty Acids and Eicosanoids
The metabolism of 20-carbon fatty acids is a complex molecular pathway involving key enzymatic steps that generate crucial biomolecules. A central enzyme in this process is the fatty acid delta-5 desaturase, primarily encoded by the FADS1 gene. [1] This enzyme catalyzes the conversion of eicosatrienoyl-CoA (C20:3) into arachidonyl-CoA (C20:4), a pivotal 20-carbon fatty acyl-CoA that serves as a precursor for various eicosanoids—signaling molecules involved in inflammation and immune responses—and a vital component of cellular membranes. [1] The efficiency of this desaturase reaction directly dictates the cellular availability of these specific fatty acyl-CoAs, thereby influencing downstream metabolic pathways.
Once synthesized, these fatty acyl-CoAs are incorporated into diverse glycerophospholipids, which are essential constituents of all biological membranes and play roles in signal transduction and energy storage. [10] For example, eicosatrienoyl-CoA and arachidonyl-CoA are specifically utilized in the biosynthesis of phosphatidylcholines, forming PC aa C36:3 and PC aa C36:4, respectively. [1] The relative concentrations of these glycerophospholipid species offer a direct reflection of the catalytic activity of the delta-5 desaturase, illustrating the intricate interconnection between fatty acid modification and the formation of complex lipids within cellular metabolic networks. [1]
Genetic Regulation of Lipid Metabolism
Genetic mechanisms exert a profound influence over an individual's lipid profile and metabolic health, particularly through genes involved in fatty acid desaturation. Polymorphisms within the FADS1 gene cluster are strongly associated with the fatty acid composition of phospholipids, highlighting the genetic control over the body's capacity to desaturate fatty acids. [11] Variations in the FADS1 gene or its regulatory elements can lead to a reduction in the catalytic activity or protein abundance of the delta-5 desaturase enzyme. [1] This genetic modulation directly impacts the concentrations of its substrates and products, creating a distinct metabolic signature.
The impact of these genetic variations is evident in metabolite profiles, where specific FADS1 genotypes correlate with the ratios of product-substrate pairs of the delta-5 desaturase reaction. [1] For instance, a decrease in FADS1 efficiency can result in elevated concentrations of glycerophospholipids containing three double bonds, such as PC aa C36:3, while simultaneously reducing the concentrations of those with four double bonds, like PC aa C36:4. [1] Such precise genetic regulation underscores the tight control over fatty acid desaturation, which in turn affects the availability of crucial polyunsaturated fatty acids for a wide range of biological functions.
Cellular and Systemic Lipid Homeostasis
Altered fatty acid availability, often driven by genetic variants like those in FADS1, can instigate widespread changes in cellular lipid homeostasis. [1] Glycerophospholipids, including phosphatidylcholines (PC), phosphatidylethanolamines (PE), and phosphatidylinositols (PI), are indispensable for maintaining membrane integrity, facilitating signal transduction, and serving as energy reserves. [10] Modifications in the efficiency of the fatty acid delta-5 desaturase reaction can significantly alter the composition of these diverse glycerophospholipid species, including specialized plasmalogen/plasmenogen phospholipids that incorporate specific arachidonyl-moieties. [1] These shifts can affect cellular function and membrane fluidity.
The metabolic ramifications extend beyond glycerophospholipids to other lipid classes, demonstrating the interwoven nature of lipid pathways. For example, alterations in phosphatidylcholine concentrations can influence sphingomyelin synthesis, given that sphingomyelin can be generated from phosphatidylcholine through the action of sphingomyelin synthase. [1] Similarly, the balance of phosphatidylethanolamines can be disrupted, affecting metabolites such as lyso-phosphatidylethanolamine, which is formed by abstracting an arachidonic acid moiety from phosphatidylethanolamines. [1] These systemic consequences illustrate how the activity of a single enzyme can profoundly impact the entire lipidome, influencing membrane dynamics and cellular signaling networks throughout the body.
Pathophysiological Implications and Disease Risk
Disruptions in fatty acid metabolism, particularly those influenced by genetic factors such as FADS1 polymorphisms, carry significant pathophysiological implications, especially concerning cardiovascular health. [3] Aberrant plasma lipid concentrations, including those of various glycerophospholipids and fatty acid derivatives, are well-established risk factors for serious conditions like coronary artery disease (CAD). [3] Maintaining a precise balance of polyunsaturated fatty acids (PUFAs) and their proper incorporation into phospholipids is crucial for preserving vascular health and mitigating inflammatory responses that contribute to disease progression.
Variations in lipid profiles, influenced by genes like FADS1, contribute to polygenic dyslipidemia, a complex condition characterized by abnormal lipid levels. [2] These systemic lipid imbalances can significantly contribute to the development of atherosclerosis, a hardening and narrowing of the arteries, and other cardiovascular pathologies. [4] A comprehensive understanding of the genetic and metabolic underpinnings of pathways related to 20-carbon fatty acids is therefore critical for elucidating disease mechanisms and identifying potential therapeutic strategies for lipid-related disorders. [3]
Pathways and Mechanisms
While eicosanodioate itself is not explicitly detailed in the provided context, the research extensively covers the pathways and mechanisms governing related fatty acids and overall lipid metabolism. This information provides a robust framework for understanding the potential biological roles and regulatory aspects of eicosanodioate as a fatty acid.
Fatty Acid Desaturation and Glycerophospholipid Synthesis
The metabolism of fatty acids involves crucial desaturation steps and their subsequent incorporation into complex lipids, which are fundamental to cellular structure and function. A key enzymatic reaction is catalyzed by delta-5 desaturase, encoded by the FADS1 gene, which converts eicosatrienoyl-CoA (C20:3) into arachidonyl-CoA (C20:4). [1] This process is vital for producing specific polyunsaturated fatty acids that are then channeled into the biosynthesis of glycerophospholipids. For instance, PC aa C36:3 and PC aa C36:4 are formed as modified substrates and products, respectively, of the delta-5 desaturase reaction, demonstrating how fatty acid composition dictates the type of complex lipids synthesized. [1] The efficiency of the FADS1 enzyme thus critically influences the availability of these specific fatty acids for downstream lipid formation, representing a significant point of metabolic control.
Membrane lipid biosynthesis, a broad category that includes glycerophospholipid formation, is a complex and essential cellular process. [10] Another central pathway in lipid metabolism is the mevalonate pathway, which is regulated by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and is responsible for synthesizing isoprenoids, precursors for cholesterol and other vital lipids. [12] These interconnected biosynthetic routes highlight how different classes of lipids share common precursors or regulatory steps, influencing the overall lipid landscape within a cell or organism.
Regulation of Lipid Metabolic Flux
The flow of fatty acids and other metabolites through these intricate pathways is precisely controlled through various regulatory mechanisms, including genetic influences and post-translational modifications. Genetic polymorphisms within the FADS1 gene can significantly alter the catalytic efficiency of the delta-5 desaturase reaction, leading to measurable changes in the circulating concentrations of its fatty acid substrates and products. [1] Such variations can result in an imbalance, with increased eicosatrienoyl-CoA (C20:3) and reduced arachidonyl-CoA (C20:4) levels, which subsequently impact the concentrations of derived glycerophospholipids like PC aa C36:3 and PC aa C36:4. [1] Beyond biosynthesis, the catabolism of fatty acids also involves regulated steps, such as beta-oxidation, which is initiated by enzymes like short-chain acyl-Coenzyme A dehydrogenase (SCAD) and medium-chain acyl-Coenzyme A dehydrogenase (MCAD) for fatty acids of differing chain lengths. [1] The efficiency of these catabolic reactions is similarly influenced by genetic variations, underscoring the tight metabolic regulation essential for maintaining lipid homeostasis. [1]
Systems-Level Integration and Transcriptional Control
Lipid metabolism is not a collection of isolated reactions but rather a highly integrated network where various pathways and regulatory elements interact to achieve systemic balance. Key transcription factors, such as SREBP-2 (Sterol Regulatory Element-Binding Protein 2), play a pivotal role in regulating the expression of genes involved in lipid synthesis, thereby establishing connections between seemingly distinct metabolic processes, such as isoprenoid and adenosylcobalamin metabolism. [13] This transcriptional governance ensures that lipid production is coordinated with cellular demands and environmental signals. Furthermore, proteins like Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) are recognized for their roles in regulating overall lipid metabolism [14] illustrating additional tiers of hierarchical regulation that integrate diverse aspects of lipid homeostasis across different tissues and physiological states. The complex interplay among these regulatory proteins and metabolic enzymes highlights the network interactions that define an organism's lipid profile.
Disease-Relevant Mechanisms and Therapeutic Implications
Dysregulation within these complex fatty acid and lipid metabolic pathways can have profound consequences for human health. Genetic variants in the FADS1 gene cluster have been consistently associated with alterations in the composition of polyunsaturated fatty acids within phospholipids [11] which can affect physiological processes and disease susceptibility. Moreover, common single nucleotide polymorphisms (SNPs) in HMGCR, a critical enzyme in cholesterol biosynthesis, have been linked to varying low-density lipoprotein (LDL)-cholesterol levels and an increased risk of coronary artery disease, partly due to their influence on alternative splicing of HMGCR mRNA. [15] Similarly, variations in ANGPTL3 and ANGPTL4 genes affect plasma lipid concentrations and are associated with the risk of developing coronary artery disease. [3] A comprehensive understanding of these pathway dysregulations is crucial for elucidating the underlying mechanisms of metabolic disorders and identifying promising therapeutic targets for intervention.
Genetic Influences on Lipid Metabolism and Related Pathways
Insights into lipid metabolites, including eicosanoids, are significantly advanced by genome-wide association studies (GWAS) that identify genetic loci influencing circulating lipid levels. These studies have uncovered numerous common variants contributing to complex traits like dyslipidemia, which involves abnormal levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides [2] For instance, polymorphisms in the FADS1 gene are strongly associated with the efficiency of metabolic reactions involving eicosanoids such as eicosatrienoyl-CoA (C20:3) and arachidonyl-CoA (C20:4), drastically impacting their concentrations [1] Understanding these genetic underpinnings is crucial for elucidating the complex interplay between genes, metabolism, and overall cardiovascular health.
Further research highlights how specific genes, such as HMGCR, affect LDL-C levels through mechanisms like alternative splicing of exon 13 [15] Additionally, natural genetic variations, like a null mutation in APOC3, have been observed to confer a favorable plasma lipid profile and provide apparent cardioprotection [16] These findings underscore the profound genetic control over lipid and eicosanoid pathways, which are integral to maintaining metabolic homeostasis and influencing disease susceptibility.
Risk Assessment and Early Detection
The genetic insights derived from population-based studies hold considerable promise for enhancing cardiovascular risk assessment and facilitating early disease detection. Genetic risk scores, compiled from multiple loci influencing lipid levels, have been shown to improve the discriminative accuracy for identifying dyslipidemia, demonstrating an improvement over models based solely on age, sex, and body mass index [7] This enhanced predictive capability suggests that genetic profiling can be a valuable tool in identifying individuals at high risk for developing lipid disorders and related cardiovascular complications.
Integrating these genetic profiles with traditional clinical risk factors, such as lipid values, age, and sex, significantly improves the classification of coronary heart disease (CHD) risk [7] Such advancements pave the way for more personalized medicine approaches, enabling clinicians to identify high-risk individuals earlier and implement targeted preventive strategies. Early detection through genetic screening can allow for timely interventions, potentially mitigating the progression of dyslipidemia and reducing the long-term burden of cardiovascular disease.
Prognostic Value and Personalized Therapeutic Strategies
The identification of genetic variants influencing lipid metabolites and eicosanoid pathways offers significant prognostic value, providing insights into disease progression and long-term health outcomes. Genetic alleles that are strongly associated with cardiovascular disease risk, particularly those impacting lipid profiles, can serve as compelling in-vivo human proof for validating potential therapeutic targets [2] This understanding is vital for developing novel pharmacological interventions and refining existing treatments.
Furthermore, knowledge of an individual's genetic predisposition to altered lipid metabolism can guide treatment selection, optimizing therapeutic regimens to achieve better patient outcomes. By considering genetic factors, clinicians can tailor lipid-lowering therapies and lifestyle interventions, moving towards a more personalized approach to patient care. Monitoring strategies could also benefit from incorporating genetic markers, allowing for more precise tracking of treatment response and disease course, ultimately improving the management and prevention of chronic conditions like cardiovascular disease.
References
[1] Gieger C et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet, 2008.
[2] Kathiresan S et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet, 2008.
[3] Willer CJ et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008.
[4] O'Donnell, C. J. et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8 Suppl 1, 2007, p. S12.
[5] Vasan RS et al. Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study. BMC Med Genet, 2007.
[6] Sabatti C, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2008;40(12):1399-1407.
[7] Aulchenko YS et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet, 2008.
[8] Benjamin EJ et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet, 2007.
[9] Wallace C, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008;82(1):139-149.
[10] Vance, J. E. "Membrane lipid biosynthesis." Encyclopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester, 2001.
[11] Schaeffer, L., et al. "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids." Hum Mol Genet, vol. 15, 2006, pp. 1745-1756.
[12] Goldstein, J. L., and M. S. Brown. "Regulation of the mevalonate pathway." Nature, vol. 343, 1990, pp. 425-430.
[13] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, 2007, pp. 359-364.
[14] Koishi, R., et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, 2002, pp. 151-157.
[15] Burkhardt R et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol, 2008.
[16] Pollin TI et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science, 2008.